Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind ...

The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...

Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

It could see competition from Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) – already a $12 billion blockbuster in other indications – as well as Sanofi’s rival oral ...

Dupixent (dupilumab) is tipped to be the market leader among a new generation of inflammation drugs, analysts Evaluate Pharma forecasting it will hit sales of nearly $5 billion by 2022.